KIT and gastrointestinal stromal tumor: In contrast, ripretinib demonstrated clinical activity compared with placebo independent of baseline mutation status in patients with fourth-line advanced GIST, including in a subgroup harboring KIT ATP-binding pocket mutations (KIT exon 13)22.